Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects
Year: 2009
Type: review
Abstract: Staphylococcus aureus in the nose is a risk factor for endogenous staphylococcal infection.UK guidelines recommend the use of mupirocin for nasal decolonization in certain groups of patients colonized with methicillin-resistant S. aureus (MRSA).Mupirocin is effective at removing S. aureus from the nose over a few weeks, but relapses are common within several months.There are only a few prospective randomized clinical trials that have been completed with sufficient patients, but those that have been reported suggest that clearance of S. aureus from the nose is beneficial in some patient groups for the reduction in the incidence of nosocomial infections.There is no convincing evidence that mupirocin treatment reduces the incidence of surgical site infection.New antibiotics are needed to decolonize the nose because bacterial resistance to mupirocin is rising, and so it will become less effective.Furthermore, a more bactericidal antibiotic than mupirocin is needed, on the grounds that it might reduce the relapse rate, and so clear the patient of MRSA for a longer period of time than mupirocin.Keywords: antimicrobials, infection control, MRSA, nosocomial, surgical Nasal decolonization of methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) is currently used in some countries for specific patient groups.For example, in the UK it is recommended 1 that carriers of MRSA, who are receiving prophylaxis for an operation, should undergo nasal decolonization with mupirocin.Mupirocin is effective at removing S. aureus from the nose over a few weeks, but nasal relapses are common within several months.2 There are few prospective randomized clinical trials (RCTs) with sufficient patients to achieve statistical significance that have been completed in this field.3 Taken together, these trials suggest that clearance of S. aureus from the nose is beneficial in some patient groups.4 This paper describes the risks, benefits and importance of patient selection in the use of mupirocin to decolonize the anterior nares.S. aureus strains MSSA lives on the skin of humans as a commensal.In developed countries 30% 5 -7 of the general adult population are colonized, although the data range from as low as 15% 8 up to 100%, in specific populations, such as those with MSSA skin infections.9 Nasal colonization (stable colonization is defined as S. aureus in the nose detected from nasal swabs taken several days apart) with strains such as MRSA is much lower, at 1% of the total population, 10 and is more frequent in certain subgroups of patients such as frequently hospitalized people, those of advancing age, patients on dialysis, AIDS patients and diabetics.1,11 Colonization with MRSA has been shown to increase the risk of infection with MRSA both immediately after colonization 12 and in long-term carriers, of whom 23% develop MRSA infections in the year following the identification of their carriage status.13 Patients who have had contact with healthcare facilities such as hospitals may be colonized in the nose with healthcare-associated (HA) MRSA.A different set of MRSA strains affects patients who have not had recent contact with healthcare units, and these strains are called community-associated (CA) MRSA.HA-MRSA usually causes diseases such as bacteraemia and infective endocarditis that tend to be more multiresistant.In contrast ... ... .. ..
DOI: 10.1093/jac/dkp159
Institutions: University College London, St George's, University of London
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2137352244
